Single Dose Pravastatin Pharmacokinetics in Pediatric Peritoneal Dialysis Patients
Status:
Terminated
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
Many children with end stage renal disease develop hyperlipidemia. HMG-CoA
(3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors, such as pravastatin, are
typical treatments for hyperlipidemia. However, we do not know how pravastatin is metabolized
in patients on dialysis. This study is designed to provide preliminary pharmacokinetic data
for pravastatin in pediatric patients on peritoneal dialysis.